<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01619293</url>
  </required_header>
  <id_info>
    <org_study_id>Wolf-5</org_study_id>
    <nct_id>NCT01619293</nct_id>
  </id_info>
  <brief_title>The Neuromarker S-100B in Patients With Different Types of Intracranial Injury</brief_title>
  <official_title>The Neuromarker S-100B in Patients With Subarachnoidal, Epidural, Subdural, and Intracerebral Hematoma, Edema Cerebri, and Concussion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Abstract:

      The most widely studied neuro-markers in traumatic brain injury (TBI) are S100B and neurone
      specific enolase (NSE). S-100B is localized in astroglia. This marker is used to predict
      neuronal damage caused by traumatic brain injury. The investigators conduct a study to derive
      and validate the measurement of S-100B in serum of patients with different types traumatic
      brain injuries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The neuromarker S-100B is a well established tool for decision making in patients traumatic
      brain injury (TBI)in Europe. In many hospitals S-100B is used routinely as a part of a set of
      high- and medium risk factors aiding the decision to perform a cranial computed tomography
      (CCT) in patients with minor head injury (MHI). In patients with severe head injury Raabe et
      al. found a significant correlation between the S-100B levels and unfavourable outcome in
      patients with severe brain injury with serum levels higher than 0.50 μg/l measured 24h after
      injury. The average level of the neuromarker, compared with other studies. The study of
      Biberthaler et al. showed highest levels in patients with epidural hematomas, followed by
      subdural, subarachnoidal and intracerebral hematomas. On the contrary the average S-100B
      levels of patients with epidural hematomas featured in a study by Unden et al. published in
      2005 displayed normal levels (&lt;0.2 μg/L). They concluded that S-100B was unreliable as a
      marker for epidural hematomas.

      Aim of the study Validation of S-100B in patients with intracerebral, epidural, subdural, and
      subarachnoidal hematoma, brain edema and concussion (Group 1-6), to find evidence which kind
      of injury leads to which level of elevation of the neuromarker measured in peripheral blood.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>S100B LEVEL</measure>
    <time_frame>14 month</time_frame>
    <description>S-100B level higher than 0.105 ug/L is held pathological</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <condition>Trauma</condition>
  <arm_group>
    <arm_group_label>Epidural H.</arm_group_label>
    <description>patients with hematoma epidurale</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subdural H.</arm_group_label>
    <description>patients with hematoma subdurale</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subarachnoidal H.</arm_group_label>
    <description>patients with hematoma subarachnoidale</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intracerebral H.</arm_group_label>
    <description>patients with hematoma intracerebrale</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E. cerebri</arm_group_label>
    <description>patients with edema cerebri</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concussion</arm_group_label>
    <description>patients with concussion</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      7ml of blood drawed from peripheral vein
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from Level 1 trauma center
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all patients with traumatic brain injury

        Exclusion Criteria:

          -  patients without traumatic brain injury
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harald Wolf, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. Trauma Surgery; Medical Univ. of Vienna, Austria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Undén J, Bellner J, Astrand R, Romner B. Serum S100B levels in patients with epidural haematomas. Br J Neurosurg. 2005 Feb;19(1):43-5.</citation>
    <PMID>16147582</PMID>
  </reference>
  <reference>
    <citation>Biberthaler P, Linsenmeier U, Pfeifer KJ, Kroetz M, Mussack T, Kanz KG, Hoecherl EF, Jonas F, Marzi I, Leucht P, Jochum M, Mutschler W. Serum S-100B concentration provides additional information fot the indication of computed tomography in patients after minor head injury: a prospective multicenter study. Shock. 2006 May;25(5):446-53.</citation>
    <PMID>16680008</PMID>
  </reference>
  <reference>
    <citation>Mussack T, Kirchhoff C, Buhmann S, Biberthaler P, Ladurner R, Gippner-Steppert C, Mutschler W, Jochum M. Significance of Elecsys S100 immunoassay for real-time assessment of traumatic brain damage in multiple trauma patients. Clin Chem Lab Med. 2006;44(9):1140-5.</citation>
    <PMID>16958611</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2012</study_first_submitted>
  <study_first_submitted_qc>June 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2012</study_first_posted>
  <last_update_submitted>November 20, 2013</last_update_submitted>
  <last_update_submitted_qc>November 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Harald Wolf, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>CCT</keyword>
  <keyword>brain</keyword>
  <keyword>trauma</keyword>
  <keyword>injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

